Use of intrauterine devices and systems by HIV-infected women

Contraception

Volumn 75, Issue 6 SUPPL., 2007, Pages

  Castaño, Paula M ^a  

^a Department of Medicine   (United States)

Author keywords

Contraception; HIV infected women; Intrauterine device; Intrauterine system

Indexed keywords

ANTIRETROVIRUS AGENT; LEVONORGESTREL;

CONTRACEPTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTRAUTERINE CONTRACEPTIVE DEVICE; ORAL CONTRACEPTION; REVIEW; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; VIRUS SHEDDING; WORLD HEALTH ORGANIZATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; INTRAUTERINE DEVICES, MEDICATED; PRACTICE GUIDELINES; SAFE SEX; WORLD HEALTH ORGANIZATION;

EID: 34248662672     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.12.010     Document Type: Review

References (25)

1. Joint United Nations Programme on HIV/AIDS. AIDS epidemic update: special report on HIV prevention (2005), UNAIDS, Geneva
2. Centers for Disease Control and Prevention. HIV AIDS Surveillance Report, 2004. Vol 16 (2005), US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta 1-46 [Accessed November 26, 2006]
3. Anderson R.N., and Smith B.L. Division of Vital Statistics. Deaths: leading causes for 2002. Natl Vital Stat Rep 53 (2005) 1-90
4. Trussel J., and Kost K. Contraceptive failure in the United States: a critical review of the literature. Stud Fam Plann 18 (1987) 237-283
5. Connor E.M., Sperling R.S., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331 (1994) 1173-1180
6. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 340 (1999) 977-987
7. Stuart G.S., Castaño P.M., Sheffield J.S., McElwee B., McIntire D.D., and Wendel G.D. Postpartum sterilization choices made by HIV-infected women. Infect Dis Obstet Gynecol 13 (2005) 217-222
8. Anderson JR, editor. A guide to the clinical care of women with HIV. Rockville (MD): Department of Health and Human Services; 2005. p. 248, 476.
9. World Health Organization. COCs and antiretroviral therapies. Medical eligibility criteria for contraceptive use. 3rd ed (2004), World Health Organization, Geneva [Annex 1]
10. Wilson T.E., Massad L.S., Riester K.A., et al. Sexual, contraceptive, and drug use behaviors of women with HIV and those at high risk for infection: results from the Women's Interagency HIV Study. AIDS 13 (1999) 591-598
11. Kanouse D.E., Collins R.L., Miu A., and Berry S.H. HIV-infected population national data. JAIDS 38 Suppl 1 (2005) S6-S7
12. World Health Organization. Medical eligibility criteria for contraceptive use. 2nd ed. (2000), World Health Organization, Geneva
13. Benki S., Mostad S.B., Richardson B.A., Mandaliya K., Kreiss J.K., and Overbaugh J. Cyclic shedding of HIV-1 RNA in cervical secretions during the menstrual cycle. J Infect Dis 189 (2004) 2192-2201
14. Kovacs A., Wasserman S.S., Burns D., and DATRI and WIHS Study Groups. Determinants of HIV-1 shedding in the genital tract of women. Lancet 358 (2001) 1593-1601
15. Mostad S.B., Overbaugh J., DeVange D.M., et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 cells from the cervix and vagina. Lancet 350 (1997) 922-927
16. Mosher W.D., Martinez G.M., Chandra A., Abma J.C., Willson S.J., and Division of Vital Statistics. Use of contraception and use of family planning services in the United States: 1982-2002. Advanced Data from Vital Health Statistics (2004) 350
17. World Contraceptive Use 2005 [wall chart]. United Nations Department of Economic and Social Affairs Population Division. Available from: http://www.un.org/esa/population/publications/contraceptive2005/WCU2005. htm Accessed.
18. Gaffikin L., Phiri A., McGrath J., Zinanga A., and Blumenthal P.D. Provider attitudes toward IUD provision in Zimbabwe: perception of HIV risk and training implications. Adv Contracept 14 (1998) 27-39
19. Heikinheimo O., Lehtovirta P., Suni J., and Paavonen J. The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women - effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod 21 (2006) 2857-2861
20. Richardson B.A., Morrison C.S., Sekadde-Kigonduy C., et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS 13 (1999) 2091-2097
21. Morrison C.S., Sekadde-Kigondu C., Sineu S.K., Weiner D.H., Kwok C., and Kokonya D. Is the intrauterine device appropriate contraception for HIV-infected women?. BJOG 108 (2001) 784-790
22. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ 304 (1992) 809-813
23. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. (2004), World Health Organization, Geneva
24. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. The copper intrauterine device as long-term contraception. J Fam Plann Reprod Health Care 30 (2004) 29-42
25. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. The levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. J Fam Plann Reprod Health Care 30 (2004) 99-109